 |
11 Diseases |  |
8 Trials |
|
8 Trials |  |
513 News |  |
| «12345678» |
- | Eucrisa (crisaborole) / Pfizer
Journal: Crisaborole (Eucrisa) for Mild to Moderate Atopic Dermatitis. (Pubmed Central) - Sep 18, 2019
No abstract available
- | Eucrisa (crisaborole) / Pfizer
New P2 trial: Study Evaluating Efficacy and Safety of Crisaborole in Adults With Stasis Dermatitis (clinicaltrials.gov) - Sep 16, 2019
P2, N=82, Not yet recruiting, Sponsor: Pfizer
- | Eucrisa (crisaborole) / Pfizer
Journal: Topical Crisaborole-A Potential Treatment for Recalcitrant Palmoplantar Psoriasis. (Pubmed Central) - Sep 14, 2019
No abstract available No abstract available
- | Eucrisa (crisaborole) / Pfizer
Journal: Crisaborole 2% Ointment (Eucrisa) for Atopic Dermatitis (Pubmed Central) - Aug 30, 2019
Evidence from phase 3 trials demonstrates crisaborole as an efficacious topical agent with a favorable safety profile and limited systemic exposure. While the efficacy of crisaborole compared to existing therapies remains unknown, crisaborole is a promising candidate in the treatment of atopic dermatitis.
- | Eucrisa (crisaborole) / Pfizer
@pfizer your recent commerical for Eucrisa is really cringy. The whole "Dad getting between daughter and boyfriend/dad intimidating daughter's boyfriend" narrative is really outdated and frankly its controlling behavior.. Y'all should really rethink it (Twitter) - Aug 20, 2019
- | Eucrisa (crisaborole) / Pfizer
Trial completion date, Trial primary completion date, Adherence: Eucrisa for Atopic Dermatitis (clinicaltrials.gov) - Aug 19, 2019
P1, N=40, Recruiting, Sponsor: Wake Forest University Health Sciences
While the efficacy of crisaborole compared to existing therapies remains unknown, crisaborole is a promising candidate in the treatment of atopic dermatitis. Trial completion date: Aug 2019 --> Feb 2020 | Trial primary completion date: Aug 2019 --> Feb 2020
- | Eucrisa (crisaborole) / Pfizer
Trial completion date, Trial primary completion date: A Study of Crisaborole Ointment 2%; Crisaborole Vehicle; TCS and TCI in Subjects Aged ≥ 2 Years, With Mild-moderate AD (clinicaltrials.gov) - Aug 14, 2019
P3b/4, N=600, Recruiting, Sponsor: Pfizer
Trial completion date: Aug 2019 --> Feb 2020 | Trial primary completion date: Aug 2019 --> Feb 2020 Trial completion date: May 2020 --> Mar 2021 | Trial primary completion date: May 2020 --> Mar 2021
- | Eucrisa (crisaborole) / Pfizer, Dupixent (dupilumab) / Sanofi, Regeneron
Journal: Atopic dermatitis: emerging therapies. (Pubmed Central) - Aug 7, 2019
This new wave of therapeutics capitalizes on the large body of work clarifying the pathogenesis of AD over the last several decades. In particular, type 2 cytokine-driven inflammation and skin barrier dysfunction are key processes underlying AD pathogenesis.
- | Eucrisa (crisaborole) / Pfizer
Trial completion date, Trial initiation date, Trial primary completion date: Steroid-reducing Effects of Crisaborole (clinicaltrials.gov) - Aug 6, 2019
P4, N=60, Recruiting, Sponsor: Johns Hopkins University
In particular, type 2 cytokine-driven inflammation and skin barrier dysfunction are key processes underlying AD pathogenesis. Trial completion date: Sep 2020 --> Dec 2020 | Initiation date: Jul 2019 --> Oct 2019 | Trial primary completion date: Jun 2020 --> Sep 2020
- | Eucrisa (crisaborole) / Pfizer
New P3 trial: A Study to Evaluate Long-Term Maintenance Treatment With Once Daily Crisaborole Ointment 2% in Pediatric and Adult Participants With Mild-to-Moderate Atopic Dermatitis (clinicaltrials.gov) - Jul 30, 2019
P3, N=700, Not yet recruiting, Sponsor: Pfizer
- | Eucrisa (crisaborole) / Pfizer
Journal: Evaluating crisaborole as a treatment option for atopic dermatitis. (Pubmed Central) - Jul 26, 2019
Since crisaborole is non-steroidal, it may reduce the need for topical corticosteroids and address steroid phobia. However, it is likely to suffer from the same factors contributing to intentional non-adherence in topicals: dissatisfaction with efficacy and inconvenience.
- | Eucrisa (crisaborole) / Pfizer
Enrollment open: Study to Assess Efficacy and Safety of Two Regimens of Crisaborole Ointment 2% in Japanese Participants Aged ≥2 Years With Mild to Moderate Atopic Dermatitis (clinicaltrials.gov) - Jul 22, 2019
P2b, N=80, Recruiting, Sponsor: Pfizer
However, it is likely to suffer from the same factors contributing to intentional non-adherence in topicals: dissatisfaction with efficacy and inconvenience. Not yet recruiting --> Recruiting
- | Eucrisa (crisaborole) / Pfizer
Biomarker, New P4 trial: Response of Children With Atopic Dermatitis (Eczema) to Eucrisa (clinicaltrials.gov) - Jul 17, 2019
P4, N=30, Not yet recruiting, Sponsor: Ann & Robert H Lurie Children's Hospital of Chicago
- | Eucrisa (crisaborole) / Pfizer
Journal: Crisaborole 2% Ointment (Eucrisa(TM)). (Pubmed Central) - Jul 11, 2019
Not yet recruiting --> Recruiting No abstract available
- | Eucrisa (crisaborole) / Pfizer
Trial completion date, Trial primary completion date: A Proof of Concept Clinical Trial Evaluating the Safety and Efficacy of Eucrisa (Crisaborole) in Patients With Seborrheic Dermatitis (clinicaltrials.gov) - Jul 10, 2019
P4, N=40, Recruiting, Sponsor: University of Alabama at Birmingham
No abstract available Trial completion date: Aug 2019 --> Sep 2020 | Trial primary completion date: Jun 2019 --> May 2020
- |||||| Eucrisa (crisaborole) / Pfizer
New trial: Improvement of Short Term Outcome of Mild to Moderate Atopic Dermatitis Using a Combination of Crisaborole and a Concomitant Topical Corticosteroid Over a 8 Week Period (clinicaltrials.gov) - Jul 5, 2019
P, N=16, Recruiting, Sponsor: Clinical Research Center of the Carolinas
- | Eucrisa (crisaborole) / Pfizer, Dupixent (dupilumab) / Sanofi, Regeneron, Kevzara (sarilumab) / Asahi Kasei, Regeneron, Sanofi
Journal: Crisaborole, Dupilumab, and Sarilumab. (Pubmed Central) - Jul 4, 2019
Trial completion date: Aug 2019 --> Sep 2020 | Trial primary completion date: Jun 2019 --> May 2020 No abstract available
- | Review, Journal: What's New in Atopic Dermatitis. (Pubmed Central) - Jul 4, 2019
Nevertheless, because not all patients respond to dupilumab and AD has a heterogeneous phenotype, more treatment options are much needed. This article reviews recent and exciting developments in AD, because ongoing or pipeline clinical trials for AD will ultimately expand and redefine a novel treatment paradigm for this common disease.
- ||| Eucrisa (crisaborole) / Pfizer
Trial completion: CrisADe CARE 1: A Study of Crisaborole Ointment 2% in Children Aged 3-24 Months With Mild to Moderate Atopic Dermatitis (clinicaltrials.gov) - May 30, 2019
P4, N=137, Completed, Sponsor: Pfizer
This article reviews recent and exciting developments in AD, because ongoing or pipeline clinical trials for AD will ultimately expand and redefine a novel treatment paradigm for this common disease. Recruiting --> Completed
- || Eucrisa (crisaborole) / Pfizer
Trial completion: Study To Assess Local Tolerability of Crisaborole 2% Ointment and Vehicle Ointment In Healthy Participants Using Subject-reported Assessments and Objective Measurements (clinicaltrials.gov) - May 23, 2019
P1, N=32, Completed, Sponsor: Pfizer
Recruiting --> Completed Recruiting --> Completed
- ||||| Eucrisa (crisaborole) / Pfizer
New P2b trial: Study to Assess Efficacy and Safety of Two Regimens of Crisaborole Ointment 2% in Japanese Participants Aged ≥2 Years With Mild to Moderate Atopic Dermatitis (clinicaltrials.gov) - May 17, 2019
P2b, N=80, Not yet recruiting, Sponsor: Pfizer
- || Eucrisa (crisaborole) / Pfizer
Trial completion date, Trial initiation date, Trial primary completion date: Steroid-reducing Effects of Crisaborole (clinicaltrials.gov) - May 15, 2019
P4, N=60, Recruiting, Sponsor: Johns Hopkins University
Recruiting --> Completed Trial completion date: Jun 2020 --> Sep 2020 | Initiation date: Apr 2019 --> Jul 2019 | Trial primary completion date: Mar 2020 --> Jun 2020
- | Eucrisa (crisaborole) / Pfizer
Journal: Treatment of psoriasis with crisaborole. (Pubmed Central) - May 15, 2019
However, there is no current literature documenting use of crisaborole for psoriasis. Here, we present two cases in which patients with psoriasis were treated successfully with crisaborole.
- | Eucrisa (crisaborole) / Pfizer, Dupixent (dupilumab) / Sanofi, Regeneron
Clinical, Journal: What's new in the management of atopic dermatitis in children and adolescents ? (Pubmed Central) - Apr 30, 2019
In order to strengthen the medical treatment, therapeutic patient education plays a supportive role in the global approach, allowing an optimized care. The Lausanne model of the Pediatric Dermatology Unit is described in this article.
- | Eucrisa (crisaborole) / Pfizer
Retrospective data, Journal: A Retrospective Study: Application Site Pain with the Use of Crisaborole, a Topical PDE4 Inhibitor. (Pubmed Central) - Apr 30, 2019
The Lausanne model of the Pediatric Dermatology Unit is described in this article. No abstract available
- | Eucrisa (crisaborole) / Pfizer, Dupixent (dupilumab) / Sanofi, Regeneron
Clinical, Journal: An update on the topical and oral therapy options for treating pediatric atopic dermatitis. (Pubmed Central) - Apr 5, 2019
When choosing the most appropriate treatment, physicians should consider the drug efficacy, potential adverse effects, patient adherence, and quality of life for both patients and caregivers. Additional studies are required to determine the safest and most effective doses for systemic therapy in childhood AD.
- | Eucrisa (crisaborole) / Pfizer
Enrollment open, Patient reported outcomes: ASPIRE: PROs & Caregiver Burden in Children With Atopic Dermatitis (clinicaltrials.gov) - Mar 13, 2019
P3, N=160, Recruiting, Sponsor: University of Rochester
Additional studies are required to determine the safest and most effective doses for systemic therapy in childhood AD. Not yet recruiting --> Recruiting
- | Eucrisa (crisaborole) / Pfizer
New P4 trial: Different Application Rates of Crisaborole Ointment 2% in Adults With Mild to Moderate Atopic Dermatitis (clinicaltrials.gov) - Mar 8, 2019
P4, N=30, Not yet recruiting, Sponsor: Innovaderm Research Inc.
- | Eucrisa (crisaborole) / Pfizer
P3 data, Journal: Clarification of methodology and further results from the pivotal phase 3 study of crisaborole for mild-moderate atopic dermatitis. (Pubmed Central) - Feb 24, 2019
Not yet recruiting --> Recruiting No abstract available
- |||| Eucrisa (crisaborole) / Pfizer
New P4 trial: Steroid-reducing Effects of Crisaborole (clinicaltrials.gov) - Feb 6, 2019
P4, N=60, Recruiting, Sponsor: Johns Hopkins University
- | Eucrisa (crisaborole) / Pfizer
Trial initiation date, Patient reported outcomes: ASPIRE: PROs & Caregiver Burden in Children With Atopic Dermatitis (clinicaltrials.gov) - Jan 24, 2019
P3, N=160, Not yet recruiting, Sponsor: University of Rochester
No abstract available Initiation date: Oct 2018 --> Feb 2019
- | Eucrisa (crisaborole) / Pfizer
Journal: Phosphodiesterase 4 (PDE4) Inhibitors. (Pubmed Central) - Jan 10, 2019
Crisaborole 2% ointment shows early and sustained improvement in disease severity and pruritus/ other AD symptoms, with burning/stinging upon application as the only related adverse event. Other PDE4 inhibitors are currently in trials with promising efficacy and safety.
- |||||| Eucrisa (crisaborole) / Pfizer
New trial: Wearable Skin Sensors to Assess Nocturnal Scratch Behavior (clinicaltrials.gov) - Dec 10, 2018
P, N=15, Not yet recruiting, Sponsor: Northwestern University
- | Eucrisa (crisaborole) / Pfizer
Enrollment open: A Proof of Concept Clinical Trial Evaluating the Safety and Efficacy of Eucrisa (Crisaborole) in Patients With Seborrheic Dermatitis (clinicaltrials.gov) - Dec 6, 2018
P4, N=40, Recruiting, Sponsor: University of Alabama at Birmingham
Other PDE4 inhibitors are currently in trials with promising efficacy and safety. Not yet recruiting --> Recruiting
- | Eucrisa (crisaborole) / Pfizer
New P1 trial: Study To Assess Local Tolerability of Crisaborole 2% Ointment and Vehicle Ointment In Healthy Participants Using Subject-reported Assessments and Objective Measurements (clinicaltrials.gov) - Nov 30, 2018
P1, N=32, Recruiting, Sponsor: Pfizer
- | Eucrisa (crisaborole) / Pfizer
Clinical, Journal, HEOR: Crisaborole Ointment Improves Quality of Life of Patients with Mild to Moderate Atopic Dermatitis and Their Families. (Pubmed Central) - Oct 23, 2018
P3
Not yet recruiting --> Recruiting Crisaborole treatment results in clinically meaningful improvement in QoL for patients and their parents/caregivers/families.
- || Eucrisa (crisaborole) / Pfizer
Enrollment open: Pilot Study Evaluating the Efficacy of a Topical PDE4 Inhibitor for Morphea (clinicaltrials.gov) - Sep 12, 2018
P2, N=20, Recruiting, Sponsor: Duke University
Crisaborole treatment results in clinically meaningful improvement in QoL for patients and their parents/caregivers/families. Not yet recruiting --> Recruiting
- | Eucrisa (crisaborole) / Pfizer
New P3 trial, Patient reported outcomes: ASPIRE: PROs & Caregiver Burden in Children With Atopic Dermatitis (clinicaltrials.gov) - Aug 24, 2018
P3, N=160, Not yet recruiting, Sponsor: University of Rochester
- |||||||||| Eucrisa (crisaborole) / Pfizer
New P3 trial: Long-Term Safety Of AN2728 Topical Ointment, 2% In The Treatment Of Children, Adolescents, And Adults (Ages 2 Years And Older) With Atopic Dermatitis (EUDRACT) - Aug 7, 2018
P3, N=517, , Sponsor: Pfizer Inc.
- | Eucrisa (crisaborole) / Pfizer
Phase classification, Adherence: Eucrisa for Atopic Dermatitis (clinicaltrials.gov) - Jul 16, 2018
P1, N=40, Recruiting, Sponsor: Wake Forest University Health Sciences
Not yet recruiting --> Recruiting Phase classification: P=N/A --> P1
- | Eucrisa (crisaborole) / Pfizer
Trial completion date, Trial initiation date, Trial primary completion date: Pilot Study Evaluating the Efficacy of a Topical PDE4 Inhibitor for Morphea (clinicaltrials.gov) - Jul 3, 2018
P2, N=20, Not yet recruiting, Sponsor: Duke University
Phase classification: P=N/A --> P1 Trial completion date: Jun 2019 --> Dec 2019 | Initiation date: Jan 2018 --> Jul 2018 | Trial primary completion date: Jun 2019 --> Dec 2019
- | Eucrisa (crisaborole) / Pfizer
New P4 trial: A Proof of Concept Clinical Trial Evaluating the Safety and Efficacy of Eucrisa (Crisaborole) in Patients With Seborrheic Dermatitis (clinicaltrials.gov) - Jun 26, 2018
P4, N=40, Not yet recruiting, Sponsor: University of Alabama at Birmingham
- || Eucrisa (crisaborole) / Pfizer
Biomarker, Trial completion, Biopsy: Crisaborole Ointment 2% Skin Biomarker Biopsy Study in Atopic Dermatitis (clinicaltrials.gov) - Jun 20, 2018
P2a, N=40, Completed, Sponsor: Pfizer
Trial completion date: Jun 2019 --> Dec 2019 | Initiation date: Jan 2018 --> Jul 2018 | Trial primary completion date: Jun 2019 --> Dec 2019 Active, not recruiting --> Completed
- | Eucrisa (crisaborole) / Pfizer
Biomarker, Enrollment closed, Biopsy: Crisaborole Ointment 2% Skin Biomarker Biopsy Study in Atopic Dermatitis (clinicaltrials.gov) - Apr 17, 2018
P2a, N=40, Active, not recruiting, Sponsor: Pfizer
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- |||| Eucrisa (crisaborole) / Pfizer
Enrollment open: CrisADe CARE 1: A Study of Crisaborole Ointment 2% in Children Aged 3-24 Months With Mild to Moderate Atopic Dermatitis (clinicaltrials.gov) - Mar 16, 2018
P4, N=125, Recruiting, Sponsor: Pfizer
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- | Eucrisa (crisaborole) / Pfizer
Trial completion: A Study of Crisaborole Ointment 2% in Adult Japanese Healthy Subjects and Adult Japanese Subjects With Mild To Moderate Atopic Dermatitis (clinicaltrials.gov) - Dec 11, 2017
P1, N=32, Completed, Sponsor: Pfizer
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- ||||| Eucrisa (crisaborole) / Pfizer
New P4 trial: CrisADe CARE 1: A Study of Crisaborole Ointment 2% in Children Aged 3-24 Months With Mild to Moderate Atopic Dermatitis (clinicaltrials.gov) - Nov 29, 2017
P4, N=125, Not yet recruiting, Sponsor: Pfizer
- Eucrisa (crisaborole) / Pfizer
Enrollment closed: A Study of Crisaborole Ointment 2% in Adult Japanese Healthy Subjects and Adult Japanese Subjects With Mild To Moderate Atopic Dermatitis (clinicaltrials.gov) - Nov 24, 2017
P1, N=32, Active, not recruiting, Sponsor: Pfizer
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- | Eucrisa (crisaborole) / Pfizer
New P2 trial: Pilot Study Evaluating the Efficacy of a Topical PDE4 Inhibitor for Morphea (clinicaltrials.gov) - Nov 22, 2017
P2, N=20, Not yet recruiting, Sponsor: Duke University
- | Eucrisa (crisaborole) / Pfizer
Enrollment open, Adherence: Eucrisa for Atopic Dermatitis (clinicaltrials.gov) - Oct 18, 2017
P=N/A, N=40, Recruiting, Sponsor: Wake Forest University Health Sciences
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting